- Home
- PCVX
PCVX
Vaxcyte Inc.
as 12-18-2024 11:41am EST
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SAN CARLOS |
| Market Cap: | 13.2B | IPO Year: | 2020 |
| Target Price: | $147.50 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $53.83 - $121.06 | Next Earning Date: | 11-05-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Vaxcyte Inc. (PCVX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| PICKERING GRANT | PCVX | CHIEF EXECUTIVE OFFICER | Dec 9 '24 | Sell | $92.70 | 2,366 | $218,252.88 | 136,369 | |
| Eydelman Mikhail | PCVX | SVP, GEN COUNSEL & CORP SEC | Dec 5 '24 | Sell | $91.66 | 5,000 | $457,433.92 | 28,697 | |
| Wassil Jim | PCVX | CHIEF OPERATING OFFICER | Dec 2 '24 | Sell | $93.06 | 8,000 | $739,884.53 | 206,822 | |
| PICKERING GRANT | PCVX | CHIEF EXECUTIVE OFFICER | Dec 2 '24 | Sell | $93.06 | 15,000 | $1,386,794.41 | 136,369 | |
| GUGGENHIME ANDREW | PCVX | PRESIDENT AND CFO | Nov 18 '24 | Sell | $86.38 | 8,000 | $686,517.55 | 109,623 | |
| PICKERING GRANT | PCVX | CHIEF EXECUTIVE OFFICER | Nov 7 '24 | Sell | $104.07 | 2,366 | $245,796.25 | 136,369 | |
| Eydelman Mikhail | PCVX | SVP, GEN COUNSEL & CORP SEC | Nov 5 '24 | Sell | $106.21 | 5,000 | $531,803.36 | 28,697 | |
| Wassil Jim | PCVX | CHIEF OPERATING OFFICER | Nov 1 '24 | Sell | $107.68 | 8,000 | $854,422.60 | 206,822 | |
| PICKERING GRANT | PCVX | CHIEF EXECUTIVE OFFICER | Nov 1 '24 | Sell | $107.40 | 15,000 | $1,602,251.52 | 136,369 | |
| GUGGENHIME ANDREW | PCVX | PRESIDENT AND CFO | Oct 18 '24 | Sell | $115.73 | 42,000 | $4,846,508.21 | 109,623 |
Latest Vaxcyte Inc. News
PCVX Breaking Stock News: Dive into PCVX Ticker-Specific Updates for Smart Investing
Insider Monkey
9 days ago
What Makes Vaxcyte (PCVX) An Investment Bet?
Clinical Trials Arena
14 days ago
Vaxcyte doses first subject in pneumococcal conjugate vaccine trial in infants
GlobeNewswire
15 days ago
Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
Insider Monkey
21 days ago
Vaxcyte (PCVX) Surged On Positive Phase 2 Data For Its Drug
MT Newswires
a month ago
Vaxcyte Insider Sold Shares Worth $686,518, According to a Recent SEC Filing
GlobeNewswire
a month ago
Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
Simply Wall St.
a month ago
We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
GuruFocus.com
a month ago
Decoding Vaxcyte Inc (PCVX): A Strategic SWOT Insight
Compare PCVX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PCVX Vaxcyte Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.